Management of cancer‐associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement

Abstract

BackgroundOptimal management of cancer‐associated thrombosis (CAT) in patients with thrombocytopenia remains difficult given competing risks of recurrent thrombosis and increased bleeding. We determine the impact of the ISTH Scientific and Standardization Committee (SCC) guidance on CAT management and thrombocytopenia on platelet transfusion, bleeding, and recurrent thrombosis. MethodsA retrospective review was performed of patients with CAT and thrombocytopenia who required anticoagulation for VTE for 11 months before and after implementation of the ISTH SCC guidance. Medical records were reviewed to identify the type of VTE event, number of platelet transfusions, incidence of bleeding, and VTE recurrence within pre‐ and postintervention time periods. ResultsA total of 41 and 80 cases were included in the preintervention and postintervention periods, respectively. The preintervention group showed a trend toward less acute VTE events (39% vs 55%; P= .05). The postintervention period had an increased per‐patient platelet transfusion (median, 2.5 vs 4; P= .05). Nonmajor bleeding was increased in the postintervention group (2% vs 16%; P= 0.03) and included all six (8%) major hemorrhages (P= .09). There was numerically less recurrent thrombosis in the postintervention group (20% vs 8%; P= .07), which was not significantly different when accounting for acuity of VTE. Management adherence was strong, at 91%, in the postintervention group. ConclusionThe ISTH guidance on management of cancer‐associated thrombosis in patients with thrombocytopenia was successfully implemented in an academic medical center. There was no significant difference in bleeding or recurrent thrombosis outcomes after adjusting for acuity of VTE.